Navigation Links
Kendle Appoints Pierre Geoffroy, MD, CM, MSc, FCFP Vice President, Early Stage
Date:6/7/2011

CINCINNATI, June 7, 2011 /PRNewswire/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced the appointment of Pierre Geoffroy, MD, CM, MSc, FCFP as Vice President, Early Stage, effective immediately.  Dr. Geoffroy brings nearly two decades of clinical development experience to this key leadership position.  He will oversee the development of Early Stage programs for customers worldwide, providing medical expertise and clinical insights for the development of safe and effective early stage clinical trials.  Dr. Geoffroy will be based out of Kendle's Early Stage unit in Toronto and will report directly to Stephen Cutler, PhD, President and CEO.

"We are thrilled to welcome Dr. Geoffroy to Kendle," said Dr. Cutler.  "He brings extensive expertise in early stage development to assist our customers in making strategic decisions related to the future of their compounds.  We look forward to his leadership as we focus on positioning Kendle's Early Stage operations for growth."

Dr. Geoffroy joins Kendle from Lambda Therapeutic Research Inc. where he served most recently as Chief Medical Officer, Vice President and Principal Investigator.  He also has served in senior clinical roles at multiple global biopharmaceutical corporations, including Senior Director, Clinical at Sanofi Pasteur; Head of Clinical Research and Senior Advisor, Drug Development at Wyeth Ayerst K.K.; Regional Director, Wyeth Research Canada; Executive Director, Medical Affairs at Hoffmann La Roche; and Associate Medical Director at SmithKline Beecham.

Dr. Geoffroy earned his medical degree, a Master of Science degree in Epidemiology and a Bachelor of Science in Nutrition, from McGill University.  He also holds a Master of Science in Nutrition from the University of Toronto.  He is certified by the Corporation des Medecins du Quebec, the College of Family Physicians of Canada, the Medical Council of Canada and the College of Physicians and Surgeons of Ontario.  He was awarded a fellowship in the College of Family Physicians of Canada in 1995.

Kendle has more than 25 years of experience in conducting Early Stage studies for more than 170 customers worldwide.  The Company's Early Stage operations consist of an 86-bed state-of-the-art inpatient unit in Toronto and a bioequivalence unit in Morgantown, W.Va. with bed space for 118 patients, allowing up to five bioequivalence studies to be conducted simultaneously.  The Toronto unit is experienced across all therapeutic areas and recognized internationally by global regulatory authorities for its expertise in conducting human abuse liability studies.  The unit houses the world's largest database of recreational drug users, ensuring that study participants can be enrolled rapidly and efficiently into these unique studies.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry.  Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide.  As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

For more information, please visit www.kendle.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to Dr. Geoffroy's anticipated contribution to Kendle's Early Stage operations growth. Words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may," and other similar expressions are intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of Kendle's management and involve a number of significant risks and uncertainties, many of which are difficult to predict and are generally beyond the control of Kendle. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional factors that could cause Kendle's results to differ materially from those described in the forward-looking statements can be found in the periodic reports filed with the Securities and Exchange Commission, which are available at the Securities and Exchange Commission's website (http://www.sec.gov) at no charge. Kendle assumes no responsibility to update any forward-looking statements as a result of new information or future developments except as expressly required by law.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology
2. Kendle Rated a "Top CRO to Work With" for Fifth Consecutive Year
3. Kendle Announces Postponement of 2011 Annual Meeting
4. INC Research to Acquire Kendle International for $15.25 per Share in Cash
5. Kendle Chairman and CEO Receives Lifetime Achievement Award at Cincinnati USA Innovation Awards
6. Kendle Executives to Share Insights at 20th Annual Partnerships in Clinical Trials Conference
7. Kendle Announces Fourth Quarter and Full-Year 2010 Results
8. Kendle Appoints Martha Feller, PhD, Vice President and Global Head, Study Start-up
9. Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO
10. Kendle to Present at Lazard Capital Markets 7th Annual Healthcare Conference
11. Kendle Announces Details Regarding Third Quarter 2010 Earnings Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
Breaking Medicine Technology:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... wound care advancements to physician colleagues, skilled nursing facility medical directors and other ... Treacherous Waters of Wound Care." , "At many of these conferences we get ...
Breaking Medicine News(10 mins):